We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

Exploratory Study Evaluating the Effects of Darifenacin on Nocturia, Sleep and Daytime Wakefulness

This study has been withdrawn prior to enrollment.
(Study was cancelled due to lack of enrollment)
ClinicalTrials.gov Identifier:
First Posted: November 23, 2009
Last Update Posted: April 13, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Novartis Pharmaceuticals
Information provided by:
Cognitive Research Corporation
The purpose of this study is to evaluate the efficacy of darifenacin in the treatment of moderate to severe nocturia in patients with overactive bladder and who do not have non-urologic causes of nocturia.

Condition Intervention Phase
Nocturia Drug: darifenacin Drug: Placebo Phase 4

Study Type: Interventional

Resource links provided by NLM:

Further study details as provided by Cognitive Research Corporation:

Enrollment: 0
Study Start Date: November 2009
Estimated Study Completion Date: July 2010
Arms Assigned Interventions
Experimental: darifenacin Drug: darifenacin
7.5 or 15 mg darifenacin, once a day for 6 weeks
Other Name: Enablex
Placebo Comparator: Sugar Pill Drug: Placebo
Placebo pill, once a day, for six weeks


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject must be aged 21-70, inclusive.
  • Subject mush have given written, personally signed and dated informed consent.
  • Subject must be diagnosed with overactive bladder.
  • Subject must have a nocturia frequency of greater than or equal to 3 episodes a night.
  • Subject must be male or non-pregnant, non-lactating female who agrees to comply with applicable contraceptive requirements.
  • Subject understands and is able, will a nd and likely to fully comply with study procedures and restrictions.

Exclusion Criteria:

  • Subject has any concurrent chronic or acute illness or unstable medical condition either treated or untreated that could confound the results of safety assessments, increase risk to the subject or lead to difficulty complying with the protocol.
  • The subject has a known or suspected allergy, hypersensitivity, or other medical contraindications to darifenacin (Enablex®) (or its components).
  • The subject has concomitant diseases in which the use of anticholinergic drugs is contraindicated, e.g. urinary retention, bladder obstruction, gastric retention and other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma, myasthenia gravis, severe hepatic impairment (Child Pugh C), severe ulcerative colitis, toxic megacolon, and patients who are at risk for these conditions.
  • Subject is taking another drug which is considered to have significant anticholinergic activity.
  • Use of drugs known to effect cognition, alertness or drowsiness, such as benzodiazepines, sedating antihistamines, opioids, or other sedative hypnotic drugs.
  • Subject has moderate to severe obstructive sleep apnea (Apnea/Hypopnea Index ≥ 15)
  • Subject has a medical condition other than OAB that is the most likely cause of the subject's nocturia (e.g., primary sleep disorder, polydipsia, polyuria).
  • Subject has taken another investigational drug or taken part in a clinical trial within the last 30 days prior to Screening.
  • The female subject is pregnant or lactating.
  • Subjects with a urine drug screen positive for stimulants, barbiturates, hallucinogens, opiates, cocaine, cannabis, or amphetamines
  Contacts and Locations
No Contacts or Locations Provided
  More Information

ClinicalTrials.gov Identifier: NCT01018225     History of Changes
Other Study ID Numbers: CRC090001
First Submitted: November 20, 2009
First Posted: November 23, 2009
Last Update Posted: April 13, 2016
Last Verified: April 2016

Additional relevant MeSH terms:
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Urological Agents